leisure time -WSS

leisure time

author：fashion 2025-10-03 01:04:31 - browse：5

3D DNA on a sheet of paper listing nucleic acid sequences — coverage from STAT — Adobe

Ultima Genomics, an upstart some observers have called a “dark horse” in the world of DNA sequencing, will soon launch a line of high-power instruments that can read a human genome for as little as $100, the company’s leadership told STAT.

The sequencer, dubbed the UG 100, is a $1.5 million machine that can read up to 20,000 human genomes a year. The reagents required to operate the instrument cost as little as $1 per billion sequenced DNA bases; that translates to $100 per genome assuming each base in the 3-gigabase human genome is read 33 times, a common industry standard. The company plans to officially launch the product at this year’s Advances in Genome Biology and Technology meeting, which kicks off in Orlando, Fla., on Feb. 5.

The product’s cost and maximum output put it roughly in the same range as a line of high-throughput instruments launched in September 2022 by Illumina, which controls an estimated 80% of the sequencing market. But Ultima is hoping it can chip into the sequencing giant’s market share among genome centers, large clinical labs, and others with an appetite for reams of genetic data by offering lower operating costs and greater flexibility.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Letters to First Opinion on caregivers, digital health, and more

WSS

With trial win, GSK could get blood cancer drug back on market

Bacterial infection may be ‘key event’ in endometriosis, study says

NIH documents show early flaws of $1.6 billion long Covid program

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Cord blood banking comes at a high cost to babies

Intellia reports positive results for its CRISPR

focus

leisure time

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Why is France rioting? What to know about the fatal police shooting of Nahel M

Hepatitis C has a cure — but many Americans still lack access to it

Cord blood banking comes at a high cost to babies

Alkermes shareholders re

7 people shot in DC, police say

In Memoriam: Notable people who died in 2023

How to increase colonoscopy rates? Looks like an AI can help

In Memoriam: Notable people who died in 2023

With trial win, GSK could get blood cancer drug back on market

explore

Option Care buys Amedisys in $3.6 billion home care deal

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Letters to First Opinion on caregivers, digital health, and more

Change Healthcare can notify patients about the breach, HHS says

The Pandemic Treaty must support building strong health systems

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

leisure time

leisure time

hotspot

leisure time